Clinical Trial: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

This study is no longer recruiting patients.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs

Purpose

Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.

Condition	Treatment or Intervention	Phase
Smoking	Drug: nortriptyline	Phase II

MedlinePlus related topics: Smoking

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further Study Details:

Study start: April 1998; Study completion: March 2001

Eligibility

Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both

Criteria

Aged 18-70,
smoking > 10 cigarettes per day,
no current major depression,
no concurrent psychiatric medications

Location Information

Colorado
VAMC, Denver, Colorado, 80220, United States

More Information

Study ID Numbers: ADRD-006-97F
Record last reviewed: June 2001
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018148
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-16

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services